The increasing burden of bladder cancer is the major factor driving the market in the European region. According to the estimates of Globocan, bladder cancer ranks fifth among the most frequently diagnosed cancer types, with about 197,105 new cases predicted in 2018 for both sexes, representing around 5% of the total cases. Moreover, increasing awareness about bladder cancer and related therapies is fueling the growth of the European bladder cancer therapeutics and diagnostics market. Apart from these, factors, like increasing awareness about bladder diseases and available therapies and innovations in novel drug development, are also contributing to the growth of the market studied. However, various factors, such as rise in the number of patent expiration is estimated to impede the growth of the studied market.
Key Market Trends
Chemotherapy Segment is Expected to Show Better Growth in the Forecast period.
Chemotherapeutics refers to the utilization of drugs to combat a certain disorder. Chemotherapy is the first choice for bladder cancer treatment. In bladder cancer, the drug is administered either intravesically or directly into the urinary bladder. The non-muscle invasive bladder cancer (NMIBC) treatment is generally performed by chemotherapy and BCG immunotherapy. There has not been much development on bladder cancer chemotherapeutic agents, during the past decade. Furthermore, the incidence of bladder cancer is high among the population, which is expected to drive the market over the forecast period.
Competitive Landscape
The market studied is highly competitive and consists of a number of major players. Companies, like AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Novartis, Pfizer Inc., Sanofi SA, etc. hold a substantial market share in the European bladder cancer therapeutics and diagnostics market.
Reasons to Purchase this report:
This product will be delivered within 2 business days.
Key Market Trends
Chemotherapy Segment is Expected to Show Better Growth in the Forecast period.
Chemotherapeutics refers to the utilization of drugs to combat a certain disorder. Chemotherapy is the first choice for bladder cancer treatment. In bladder cancer, the drug is administered either intravesically or directly into the urinary bladder. The non-muscle invasive bladder cancer (NMIBC) treatment is generally performed by chemotherapy and BCG immunotherapy. There has not been much development on bladder cancer chemotherapeutic agents, during the past decade. Furthermore, the incidence of bladder cancer is high among the population, which is expected to drive the market over the forecast period.
Competitive Landscape
The market studied is highly competitive and consists of a number of major players. Companies, like AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Novartis, Pfizer Inc., Sanofi SA, etc. hold a substantial market share in the European bladder cancer therapeutics and diagnostics market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline PLC
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Endo International plc
- Janssen Pharmaceutical Companies (Johnson & Johnson)
Methodology
LOADING...